These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29468438)

  • 1. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
    Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
    J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
    Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
    Hochhaus A; Masszi T; Giles FJ; Radich JP; Ross DM; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; García-Gutiérrez V; Gattermann N; Wiktor-Jedrzejczak W; le Coutre PD; Martino B; Saussele S; Menssen HD; Deng W; Krunic N; Bedoucha V; Saglio G
    Leukemia; 2017 Jul; 31(7):1525-1531. PubMed ID: 28218239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX
    Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
    Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
    Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
    Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
    Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
    Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
    Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
    Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
    Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
    Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
    Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
    Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
    Takahashi N; Nishiwaki K; Nakaseko C; Aotsuka N; Sano K; Ohwada C; Kuroki J; Kimura H; Tokuhira M; Mitani K; Fujikawa K; Iwase O; Ohishi K; Kimura F; Fukuda T; Tanosaki S; Takahashi S; Kameoka Y; Nishikawa H; Wakita H;
    Haematologica; 2018 Nov; 103(11):1835-1842. PubMed ID: 29976734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.